GLPwatch
Papers (10376)
Page 82 of 173, ranked by citation count.
- Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.
- Liraglutide treatment effects on rat ovarian and uterine tissues.
- Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
- Glucocorticoids Inhibit Basal and Hormone-Induced Serotonin Synthesis in Pancreatic Beta Cells.
- Principal components analysis on genes related to inflammasome complex and microglial activation in the hypothalamus of obese mice treated with semaglutide (GLP-1 analog).
- Semaglutide in renal ischemia-reperfusion injury in mice.
- Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction.
- The design of the liraglutide clinical trial programme.
- An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
- Storage and Utilization of Glycogen by Mouse Liver during Adaptation to Nutritional Changes Are GLP-1 and PASK Dependent.
- PDGF Facilitates Direct Lineage Reprogramming of Hepatocytes to Functional β-Like Cells Induced by Pdx1 and Ngn3.
- Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus.
- Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy.
- Dulaglutide and renal protection in type 2 diabetes.
- Liraglutide: effects beyond glycaemic control in diabetes treatment.
- Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis.
- Medical and surgical treatment of postbariatric hypoglycaemia: Retrospective data from daily practice.
- Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression.
- Liraglutide preconditioning attenuates myocardial ischemia/ reperfusion injury via homer1 activation.
- Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.
- Overview of new antiobesity drugs.
- Liraglutide-induced acute pancreatitis.
- The role of incretin receptor agonists in the treatment of obesity.
- Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events.
- The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype.
- Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia.
- Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.
- Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?
- Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?
- Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
- Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3.
- Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.
- Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide.
- High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management.
- Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
- Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.
- Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
- Repression of sterol regulatory element-binding protein 1-c is involved in the protective effects of exendin-4 in pancreatic β-cell line.
- PEGDA/HA mineralized hydrogel loaded with Exendin4 promotes bone regeneration in rat models with bone defects by inducing osteogenesis.
- Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.
- Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
- Pro-healing impact of liraglutide on skin wounds in normoglycemic mice.
- Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment.
- Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.
- Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m<sup>2</sup>, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.
- Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.
- Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway.
- 68Ga-NOTA-Exendin-4 PET/CT in Localization of an Occult Insulinoma and Appearance of Coexisting Esophageal Carcinoma.
- Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
- Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
- Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.
- Semaglutide for Weight Loss: Was It Worth the Weight?
- Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
- Tirzepatide: Clinical review of the "twincretin" injectable.
- Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.
- Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.
- Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature.
- Semaglutide and the future of obesity care in the UK.